NAMI-A

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

NAMI-A 是一种钌基试剂，其特征在于对肿瘤转移的选择性活性，抑制粘附和迁移。

NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases,inhibits the adhesion and migration.In vitro:NAMI-A can significantly affect tumor cells with metastatic ability.The half lifetime of NAMI-A elimination from the lungs is longer than for liver, kidney, and primary tumor. NAMI-A bound to collagen is active on tumor cells as shown in vitro by an invasion test, using a modified Boyden chamber and Matrigel, and it inhibits the matrix metallo-proteinases MMP-2 and MMP-9 at micromolar concentrations. The ruthenium drug NAMI-A inhibits the adhesion and migration of colorectal cancer cells. NAMI-A decreases α5β1 integrin expression and FAK auto-phosphorylation on Tyr 397. In vivo: The reference for NAMI-A is 35 mg/kg/day.

——

——

——

Angiogenesis

FAK

FAK

——

——

201653-76-1

458.18

C8H15Cl4N4ORuS

>98% (HPLC)

In Vitro:?H2O 中的溶解度 : 8.28 mg/mL (18.07 mM; 超声加热助溶)

[H+].O=[S](C)(C)[Ru+3]([Cl-])([Cl-])([Cl-])([Cl-])[N]=1C=CNC1.N=1C=CNC1

——

(-20℃)

With Ice Pack

≥ 2 years